In an interview with ET Now, Sunil Singhania, Head Equities,
Reliance Mutual Fund, says the composition of the market movement is definitely
going to change, but the downside to the market looks limited. Excerpts:
ET Now: Can the market retest December lows?
Sunil Singhania: We definitely do not expect that. At the
same time, the whole composition of the market movement is changing. The
earlier bellwether stocks are no longer the same. Therefore, the composition of
the market movement is definitely going to change, but we definitely believe
the downside is going to be limited.
ET Now: Your exposure to pharma has worked for you like a
charm. You have 18% exposure to pharma, and out of your top 5 holdings, 3 are
pharma names that are at an all-time high. That is an aggressive bet which has
worked for you. Are you still bullish on it?
Sunil Singhania: I will give you a perspective of what we
did. The consumption story in India has been played out significantly. We felt
it was a good story and a good theme, but it was slightly pricy in terms of
stock valuations. We felt that pharma had the benefit of the consumption theme
domestically, because domestic pharma has been growing at upwards of 15-18% for
the last 2-3 years. Also, there was an export story in terms of a massive
opening up of the generic markets in the US, Europe and in other countries. The
Indian companies were now mature enough to take benefit of that. Further, the
currency also helped.
So it has been a combination of being underweight on some
sectors, which are similar but which looked a little pricy, and being
overweight on pharma, which had similar characteristics, ROE, neat and clean
balance sheets and also the added opportunity of the export front. And we are
lucky to some extent. We hope the performance continues and at this point of
time, we continue to be positive on the pharma sector.
ET Now: So you are in no hurry to reduce your exposure to
pharma stocks?
Sunil Singhania: Reduction and addition is a day to day...
ET Now: 1% here, 1% there, that is fair enough, but what
about...?
Sunil Singhania: At this point of time, we continue to be
positive. Obviously there are some segments of the pharma sector which might
face some headwinds because of the government policy of generalisation even on
the domestic market. But by and large, the companies are growing significantly
well, and the ROEs and the managements are good and even quite comfortable.
ET Now: But your bias is clearly more towards the Indian
pharma companies?
Sunil Singhania: Again, it is a mix. In some funds, we have
exposure to multinational pharma companies, but at this point in time, the
company is obviously in the portfolio, and there are others we have big
positive bias on.
ET Now: If I look at the portfolio of Reliance Growth Fund,
the only consumption space you are bullish on is liquor. What makes you bullish
on liquor stocks?
Sunil Singhania: I do not want to mention particular
companies, but if you analyse the cigarette market and the liquor market, both
are vices. Cigarettes are actually very injurious to health. Liquor, to some
extent, is a social vice, but it is not as harmful to human health, but you see
the market cap of the cigarette industry in India and the market cap of the
liquor industry in India -- obviously one industry has done well because of one
company which is supposed to be a very clean company and rightly so. In the
liquor industry, however, the dominant player has been plagued by other
non-fundamental problems.
So our call is that the liquor industry has got huge
potential in India. It has probably the best consumption theme as far as India
is concerned. It is becoming more and more socially acceptable in India. We
have a young population who is more prone to accepting social drinking, who
drinks socially and responsibly, and the valuations are in favour. So we use
this opportunity of non-fundamental problems to build positions there.
ET Now: Your current declared portfolio shows you are
bullish on banks, but within the banking space, you pretty much like all the
banking businesses. You have exposure to SBI, ICICI Bank and Federal Bank in
the PSU, private and small private banks space, respectively. So you are pretty
much bullish on the entire banking spectrum?
Sunil Singhania: No. Obviously we understand NPLs and
restructured assets are a big problem. Our call has been to move towards larger
banks, away from the smaller banks for some time. So the biggest banks in our
portfolio are the largest banks and among the smaller banks, we have stuck to
banks where we feel that the perceived asset quality is better than the street.
So across funds we have more or less moved towards larger
banks vis-a-vis the smaller banks. And at an opportune time, once the
environment on the economy clears, we will take a call on whether we need to
rejig the portfolio as far as the banking space is concerned.
ET Now: In our previous conversation, you made a case for
buying PSU banks. Are you now making a case not to buy PSU banks?
Sunil Singhania: No, we are taking a PSU banking versus
private banking stand. Obviously private banks are slightly less prone to NPL
problems for the simple reason because they do not have the kind of social
obligation as some of the PSU banks have.
But the call is that in this kind of an environment, smaller
banks might get hit more if one or two big accounts turn NPLs or turn into
restructured assets. So the call is more towards larger banks.
We are not taking a PSU versus private stand because while
private banks are good, they are also priced accordingly. PSU banks have some
issues, but their valuations have also come down accordingly. But the call from
our side is to be in larger banks, which might be able to withstand near-term
NPL or restructuring issues slightly more strongly than the smaller banks.
ET Now: Why are you so negative on autos?
Sunil Singhania: I do not think we are negative on autos.
ET Now: You have got 1 or 2 exposure there, no exposure...
Sunil Singhania: No. In fact, in some of our funds, we have
a huge exposure to auto. In India, auto is a great story structurally. But auto
is also slightly negatively correlated with interest rates. With the interest
rate scenario improving now, there is near-term headwinds in terms of auto
sales, because of the way the economy is progressing and also because of the
perception that monsoon might not be as good.
So the purchase is being shifted, but we will continue to
track it closely. In fact, we feel that in future the support auto sector
companies, i.e. engineering and auto ancillary companies, would be very
interesting to look at.
So we are not negative, but in the near term, there might be
months when you have some disappointing sales.
ET Now: Looking at Infosys and TCS, do you think IT or
largecap IT stocks could go through a process of de-rating?
Sunil Singhania: TCS is almost at an all-time high barring
the past few days, but it clearly reflects that even within this sector, all
companies are not going to move together. So there is a huge diversion of
performance within the IT segment. So one company is down significantly like
20% year to date, but some of the other companies are up 15-17-20% year to
date.
Some of the smaller IT companies have been doing very well,
and many of these IT companies are trading at 5 to 7 year highs. The sector is
superb. As a country with a huge working population, we have an advantage. The
cost pressures are slowly coming under control. All it will take is some
revival in the global economy before investors start to look at this sector
again.
So we will closely watch this sector, and we do believe that
stock specifics even within the sector will be more important.
Source: http://articles.economictimes.indiatimes.com/2012-07-20/news/32748646_1_pharma-sector-pharma-stocks-domestic-pharma/2